key: cord-0078373-6paj4zli authors: Weber, Sven C.; Danne, Friederike; Kieslich, Moritz; Krauss, Annemarie; Berger, Felix; Sallmon, Hannes title: Case Anecdotes, Opinion and Comment Sotrovimab in pediatric cardiac transplant recipients with SARS-CoV2 infection date: 2022-05-20 journal: J Heart Lung Transplant DOI: 10.1016/j.healun.2022.05.003 sha: 5241abcba37af62d7f400ffa952108c07e0cdf85 doc_id: 78373 cord_uid: 6paj4zli nan Cardiac transplant recipients infected with SARS-CoV2 represent a high-risk cohort for a severe and potentially life-threatening course of coronavirus disease 2019 . Conway et al. have recently shown that 21% among all pediatric SARS-CoV2 infected postheart transplantation patients were hospitalized, 7% required intensive care and 1% were mechanically ventilated. 1 However, data on potential treatment options in pediatric COVID-19 patients are still sparse. Recently, the National Institutes of Health (NIH) recommended the use of SARS-CoV2 antibody therapy in immunocompromised patients with mild to moderate COVID-19. An additional pediatric consensus statement advocated the use of SARS-CoV2 monoclonal antibody (mAB) therapy in order to avoid severe illness in infected adolescents ≥ 12 years. 2 Among the available mABs, sotrovimab is a newly developed immunoglobulin G-1 (IgG-1kappa) mAB which provides sufficient passive immunization against SARS-CoV2, including the B.1.1.529 (omicron) variant, and recently received emergency authorization by regulatory authorities. 3 We herein report on nine pediatric cardiac transplant recipients infected with SARS-CoV2 who received treatment with sotrovimab (TABLE) . In all patients, infections were confirmed by quantitative polymerase-chain-reaction (qPCR). Children ≥ 20 kg received the full dose of sotrovimab recommended for adults (500 mg) intravenously 4 and children < 20 kg received 250 mg. Sotrovimab was administered to all non-hospitalized patients over a period of 30-60 min in the pediatric emergency department. After an additional surveillance period of 4 hours under close monitoring patients were allowed to go home. 5 Of, note, sotrovimab treatment was initiated within the first 72 hours after the onset of symptoms in all of our patients. Six out of nine patients were younger than 12 years and thus received sotrovimab offlabel after informed consent had been obtained from their parents/legal caregiver. Six patients were vaccinated prior to their SARS-CoV2 infection (all Comirnaty®, Biontech/Pfizer, Germany). Only one patient required hospitalization for four days. The patient received sotrovimab upon admission and was hospitalized for surveillance due to moderate respiratory symptoms (cough and mild dyspnea) without the need for oxygen or non-invasive respiratory support. Five other patients had only mild respiratory symptoms (cough, common cold-like symptoms, fatigue, no dyspnea) and three patient were only minimally symptomatic (rhinitis). Of note, results of routine cardiac examinations (troponin T, echocardiogram, electrocardiogram) provided stable results in all patients, indicating the absence of any cardiac involvement during SARS-CoV2 infection. None of the patients experienced any adverse reactions or side effects, such as allergic symptoms or anaphylaxis, 4, 5 and all patients showed full-recovery within three weeks. While in our cohort only one out of nine patients was hospitalized (~11 % as compared to the previously reported 21 %) 1 , conclusions regarding potential efficacy of sotrovimab in pediatric cardiac transplant recipients cannot yet be drawn due to the following reasons: First, our small observational cohort lacks an appropriate control group. Second, changes in hospitalization rates may become evident over time as providers gain more experience with SARS-CoV2 infected pediatric heart transplant patients. In addition, viral variants likely affect efficacy of different mAB treatments. In conclusion, this is the first report that indicates feasibility and safety of sotrovimab application within the first 72 hours after the onset of symptoms in SARS-CoV2 infected pediatric cardiac transplant recipients, including those < 12 years. However, further systematic investigations in multi-institutional cohorts are warranted in order to establish safety and efficacy of sotrovimab treatment in immunocompromised pediatric patients after heart transplantation. Early report from the Pediatric Heart Transplant Society on COVID-19 infections in pediatric heart transplant candidates and recipients Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents An infectious SARS-CoV-2 B Omicron virus escapes neutralization by therapeutic monoclonal antibodies SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19 COVID-19 Therapeutics for Nonhospitalized Patients Table: Clinical Characteristics of Pediatric Cardiac Transplant Recipients Treated With Sotrivimab for SARS-CoV2 Infection AoVS -aortic valve stenosis; CACNA1C -Calcium voltage-gated channel subunit alpha1 C; ccTGA -Congenitally corrected transposition of the great arteries HTx -Heart transplantation; LQTS -Long QT-syndrome, LVOTO -left ventricular utflow tract obstruction, MMF-Mycophenolat mofetil VSD -Ventricular septal defect Disclosures: All authors declare that do not have any conflicts of interest to disclose.